This plain language summary from Future Oncology describes long-term results from the RESONATE-2 study in which participants were treated with ibrutinib or with chlorambucil, and then followed for up to 8 years.

Read the full article here.

The original article on which this plain language summary is based is titled ‘Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia’ and was published in Blood Advances. Read the original article here.